Justyna Rajewska-Tabor

Dr. Justyna Rajewska-Tabor

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
ACAleksandra Cieplucha
Aleksandra Cieplucha
OTOlga Trojnarska
Olga Trojnarska
ABAgnieszka Bartczak-Rutkowska
Agnieszka Bartczak-Rutkowska
AKAnna Kociemba
Anna Kociemba
JRJustyna Rajewska-Tabor
Justyna Rajewska-Tabor
MPMałgorzta Pyda
Małgorzta Pyda

21 December 2023 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
JRJustyna Rajewska-Tabor
Justyna Rajewska-Tabor
PSPatrycja Sosińska-Zawierucha
Patrycja Sosińska-Zawierucha
MPMalgorzata Pyda
Malgorzata Pyda
MLMaciej Lesiak
Maciej Lesiak
ABAndrzej Bręborowicz
Andrzej Bręborowicz
Severe acute respiratory syndrome coronavirus-2 causes hyperinflammation and activation of coagulation cascade and, as a result, aggravates endothelial cell dysfunction. N-acetylcysteine and Sulodexide have been found to mitigate endothelial damage. The influence on coronary artery endothelial cells of serum collected after 4 ± 1 months from coronavirus infection was studied. The concentrations of serum samples of interleukin 6, von Willebrand Factor, tissue Plasminogen Activator, and Plasminogen Activator Inhibitor-1 were studied. The cultures with serum of patients after coronavirus infection were incubated with N-acetylcysteine and Sulodexide to estimate their potential protective role. The blood inflammatory parameters were increased in the group of cultures incubated with serum from patients after coronavirus infection. Supplementation of the serum from patients after coronavirus infection with N-acetylcysteine or Sulodexide reduced the synthesis of interleukin 6 and von Willebrand Factor. No changes in the synthesis of tissue Plasminogen Activator were observed. N-acetylcysteine reduced the synthesis of Plasminogen Activator Inhibitor-1. N-acetylcysteine and Sulodexide increased the tPA/PAI-1 ratio. N-acetylcysteine may have a role in reducing the myocardial injury occurring in the post-COVID-19 syndrome. Sulodexide can also play a protective role in post-COVID-19 patients.

1 October 2021 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
ACA Cieplucha
A Cieplucha
OTO Trojnarska
O Trojnarska
JRJustyna Rajewska-Tabor
Justyna Rajewska-Tabor
AKA Katarzynska-Szymanska
A Katarzynska-Szymanska
PMPrzemysław Mitkowski
Przemysław Mitkowski
MPMałgorzta Pyda
Małgorzta Pyda
Ebstein anomaly (EA) is characterized by anomalous tricuspid valve resulting in the whole right heart's distorted anatomy. Heart failure is the most frequent complication in adults with EA. Recently more attention is also paid to the left ventricle. Some limited echocardiographic data suggest a markedly increased occurrence of the left ventricular hypertrabeculation, by some authors called a non-compacted myocardium. Currently, cardiac magnetic resonance (CMR) is a gold standard in the evaluation of hypertrabeculation. However, different diagnostic criteria and discrepancies in the study outcomes make the clinical interpretation of this phenomenon questionable and challenging. To determine the frequency of the left ventricular hypertrabeculation among adults with EA; to assess its association with the ventricular size and function and the markers of heart failure. Study group consisted of 35 unoperated adults (mean age 41.9±14.8 years) with Ebstein anomaly. The study protocol included: a) cardiac magnetic resonance (CMR) with the assessment of the left ventricle (LV) and functional right ventricle (fRV), including ejection fraction (EF), end-diastolic, end-systolic, and stroke volumes indexed by body surface area (respectively: EDVind, ESVind, SVind), and presence of hypertrabeculation defined according to Jacquier (1) as trabeculation mass >20% of the LV mass; b) cardiopulmonary tests with the assessment of peak oxygen consumption (peak VO2, % of predicted peak VO2), ventilation/carbon dioxide slope (VE/VCO2 slope) c) brain natriuretic peptide (BNP). Left ventricular hypertrabeculation was present in 13 (37.1%) patients. We demonstrated no difference between patients with and without LV hypertrabeculation regarding: s the left ventricular size and function [LV EDV ind (ml/m2): 65.9±11.2 vs. 67.8±16.6, p=0.737; LV SV ind (ml/m2): 37.4±8.6 vs. 40.1±9.5, p=0.48; LV EF (%): 56.9±8.6 vs. 59.9±7.9, p=0.415]; the right ventricular size and function [fRV EDV ind (ml/m2): 147.8±71.1 vs. 126.9±42.2, p=0.438; fRV SV ind (ml/m2): 22.0±16.4 vs. 29.2±11.9, p=0.302; fRV EF (%): 38.0±12.0 vs. 46.0±10.4, p=0.184]; the heart failure markers, including cardiopulmonary parameters [peakVO2 (ml/kg/min): 25.0±5.8 vs. 25.4±5.1, p=0.855; % peak VO2: 69.4±15.5 vs. 78.9±23.1, p=0.284; VE/VCO2slope: 24.4±2.5 vs. 25.9±4.1, p=0.332] and BNP [52.1±40.3 vs. 59.3±41.8 (pg/ml), p=0.663]. Left ventricular hypertrabeculation demonstrated by cardiac magnetic resonance is a phenomenon frequently occurring among adults with Ebstein anomaly. However, its presence is not associated with both ventricles' worse function nor with reduced exercise capacity. Therefore, the clinical relevance of left ventricular hypertrabeculation in this population remains questionable and requires further prospective studies. Type of funding sources: None.

1 June 2021 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
JRJustyna Rajewska-Tabor
Justyna Rajewska-Tabor
WEW Elikowski
W Elikowski
Magdalena JanusMagdalena Janus
Magdalena Janus
SRS Rozmiarek
S Rozmiarek
MLMaciej Lesiak
Maciej Lesiak
MPMałgorzta Pyda
Małgorzta Pyda
Funding Acknowledgements: Type of funding sources: None. Introduction: Cardiovascular involvement during SARS-CoV-2 infection has been described previously in hospitalized patients mainly. The percentage of patients vulnerable after coronavirus infection disease 2019 (COVID-19) is still being under discussion. What remains unknown is the impact of coronary virus on heart on mildly symptomatic patients. Aim of the study The aim of the study was to evaluate cardiac injury 4 months after COVID-19 in mildly symptomatic patients. Material and methods 80 patients successfully cured from COVID-19 were evaluated between 3-4 months after the disease. The study group consisted of 30 males (37.5%) and 50 females (62.5%) with the mean (SD) age 45 (11) years. All patients had laboratory tests, electrocardiogram (ECG) and cardiac magnetic resonance (CMR) done. Cardiac magnetic resonance was performed on 1,5T scanner (Aera, Siemens, Germany). During the CMR study cine imagines, T2-mapping, T1-mapping before and after gadolinium, extracellular volume (ECV) assumption and late gadolinium enhancement were done. Additionally global longitudinal strain was examined. Dedicated software (QMass, Medis, Holland) was used. Results: During SARS-CoV-2 infection 31 patients (39%) had comorbidities, 16 patients (20%) were hospitalized for 3-5 days. 64 (80%) recovered at home, from whom 10 (12.5%) were asymptomatic. At the time of CMR, high-sensitivity troponin I (hs TnI) was in the normal range in all subjects, while 8 (10%) subjects showed slightly elevated NT pro-BNP and 11 (14%) subjects showed elevated D-dimers. Based on myocardial injury detected during CMR the patients were divided into 2 groups. CMR examination showed myocardial injury in 34 (42.5%) patients. The patients with myocardial injury had significant higher native T1 (1011ms in injured group vs 967ms in group without injury; p = 0.006) and ECV (29.5% vs 27% respectively; p = 0.003). NT pro-BNP levels were elevated in 9 patients with myocardial injury on CMR. None of the patients without myocardial injury had NT pro-BNP elevated (p = 0.007). Conclusions: This study indicates that even in mildly symptomatic patients there are occurrences of myocardial injury. The cardiac magnetic resonance is a useful tool for diagnosing myocardial injury after COVID-19.

24 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JRJustyna Rajewska-Tabor
Justyna Rajewska-Tabor
PSPatrycja Sosińska-Zawierucha
Patrycja Sosińska-Zawierucha
MPMalgorzata Pyda
Malgorzata Pyda
ABAndrzej Bręborowicz
Andrzej Bręborowicz
Severe acute respiratory syndrome coronavirus-2 causes hyperinflammation and activation of coagulation cascade and in the result aggravates endothelial cell dysfunction. N-acetylcysteine and Sulodexide have been found to mitigate endothelial damage. The influence on coronary artery endothelial cells of serum collected after 4+/-1 months from coronavirus infection was studied. The concentrations of serum samples of interleukin 6, von Willebrand Factor, tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 were studied. The cultures with serum of patients after coronavirus infection were incubated with N-acetylocysteine and Sulodexide to estimate their potential protective role. The blood inflammatory parameters were increased in the group of cultures incubated with serum from patients after coronavirus infection. Supplementation of the serum from patients after coronavirus infection with N-acetylcysteine or Sulodexide reduced the synthesis of interleukin 6, von Willebrand Factor. No changes in the synthesis of tissue Plasminogen Activator were observed. N-acetylcysteine reduced the synthesis of Plasminogen Activator Inhibitor-1. N-acetylcysteine and Sulodexide increased the tPA/PAI-1 ratio. N-acetylcysteine may have a role in reducing the myocardial injury occurring in the post-COVID-19 syndrome. Sulodexide can also play a protective role in post-COVID-19 patients.

1 January 2018
Verified
Journal Article
Open access
JRJustyna Rajewska-Tabor
Justyna Rajewska-Tabor
BZBartosz Zabicki
Bartosz Zabicki
MHMichal Hrycow
Michal Hrycow
SRSzymon Rozmiarek
Szymon Rozmiarek
MPMalgorzata Pyda
Malgorzata Pyda